

1 **The mitochondrial gene CMPK2 functions as a rheostat for macrophage homeostasis in**
2 **inflammation.**

3 Prabhakar Arumugam^{1,2}, Meghna Chauhan^{1,2}, Thejaswitha Rajeev¹, Rahul Chakraborty^{1,2},
4 Deepthi Shankaran^{1,2}, Sivaprakash Ramalingam^{1,2}, Sheetal Gandotra^{1,2}, Vivek Rao^{1,2*}

5 1-CSIR- Institute of genomics and Integrative Biology, Mathura Road, New Delhi-110025
6 India.

7 2- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India

8 *Corresponding author: Tel: +91 11 29879229, E-mail: vivek.rao@igib.res.in

9 Running title: CMPK2 regulates macrophage inflammation

10 Key words: CMPK2, M1 macrophage, Immuno-metabolism, Mitochondria, infection

11 **ABSTRACT:**

12 Mitochondria, in addition to cellular energy production, are now being recognized as regulators of
13 the innate immune response of phagocytes. Here we found that down regulation of the
14 mitochondria associated enzyme, Cytidine Monophosphate Kinase 2 (CMPK2), results in a
15 significant de-regulation of resting immune homeostasis of macrophages, presenting as an
16 enhanced expression of the pro-inflammatory genes- IL1 β , TNF α and IL8 in these cells
17 associated with enhanced mitochondrial ROS and altered mitochondrial shape. Contrary to
18 expectation, these phenotypic changes were also preserved in cells with constitutive over
19 expression of CMPK2 thereby implicating an important role for this gene in the regulation of
20 inflammatory balance of macrophages. Interestingly, long term modulation of CMPK2 expression
21 resulted in increased glycolytic flux in both the silenced and over-expressing cells akin to the
22 altered physiological state of activated M1 macrophages. While infection induced inflammation
23 for restricting pathogens is regulated, our observation of a total dysregulation of basal
24 inflammation by bidirectional alteration of CMPK2 expression, only highlights a critical role of this
25 gene in mitochondria mediated control of inflammation.

26 **Abbreviations:** ROS- reactive oxygen species, IFN- Interferon, LPS-lipopolysaccharide, TLR-
27 toll like receptors.

28

29 **Introduction:**

30 Eukaryotic cells are endowed with a versatile organelle- mitochondria that serves as an energy
31 hub fueling cellular processes. The enormous metabolic flexibility offered by mitochondria
32 resident processes forms the basis of cellular plasticity facilitating fine-tuned responses to
33 physiological conditions^{1, 2}. The importance of mitochondrial health in terms of physiology,
34 network architecture in immune cell function and response to infection is well recognized^{3, 4, 5}.
35 Activated M1 polarized macrophages demonstrate an important shift in the metabolic state relying
36 completely on glycolysis for increased and faster production of energy^{5, 6, 7, 8, 9}. This transition is
37 associated with a distinctive change in mitochondrial structure and a diminished reliance on
38 mitochondrial oxidative phosphorylation and increased production of mitochondrial ROS^{10, 11, 12,}
39 ¹³.

40 Intracellular infections compel host macrophages to activate selective cellular pathways to the
41 inflammatory M1 profile of response resulting in activation of bactericidal pathways. The duality
42 of the inflammatory response: controlling bacteria efficiently in a controlled fashion (host
43 beneficial) to an extensive tissue damage on uncontrolled activation (detrimental) signifies the
44 need to effectively regulate the onset and end of the inflammation. Several mechanisms have
45 been defined for control of inflammation by host phagocytes ^{14, 15, 16, 17}. Studies in the last decade
46 have implicated a determinant connection between mitochondria and the inflammation balance
47 of immune cells ^{18, 19, 20}. With a central role of mitochondria in cellular metabolism and physiology,
48 it is logical to presume stringent control of organelle integrity to achieve homeostasis even under
49 stress. This necessitates high degree of flexibility in sense and response mechanisms of the
50 immune cells.

51 We demonstrate that the mitochondrial resident kinase – CMPK2, is an important modulator of

52 inflammation in macrophages. CMPK2 is actively induced by infection in macrophages and
53 responds primarily to TLR4 stimulation. Expression of CMPK2 is tightly regulated with a sharp
54 increase in expression following infection of macrophages. Interestingly, macrophages with
55 constitutively altered expression (stable silencing or over- expression) of CMPK2, demonstrated
56 heightened levels of basal expression of inflammatory gene resembling the M1 macrophages.
57 Concordant with this, we also observe a significant shift in macrophage metabolism to reliance
58 on glycolysis and increase in mitochondrial ROS. A crucial role of regulated CMPK2 expression
59 in controlling bacterial growth effectively provides an important link between mitochondrial
60 metabolism and innate response kinetics of macrophages.


61 **Results:**

62 **Macrophages respond to infection/ TLR4 stimulation by inducing *CMPK2*.**

63 A well-orchestrated transcriptional response is initiated in macrophages infected with intracellular
64 and extracellular bacteria. With type I IFN as one of the earliest responses of infected
65 macrophages^{21, 22, 23}, it was not surprising that the interferon stimulated gene (ISG)- *CMPK2* also
66 showed significant increase in expression following Mtb infection. Infected macrophages showed
67 a steady increase in *CMPK2* expression from 15-fold of expression by 6h and attaining peak
68 levels of ~140 fold by 12h and thereafter maintained to greater than 100- fold even at 24h of
69 infection (Fig. 1A). In line with previous reports²⁴, we also observed nearly 20- fold increase in
70 *CMPK2* expression in response to LPS stimulation while the other TLR ligands failed to alter this
71 gene (Fig. 1B). This was also evident as a steady increase in CMPK2 protein levels in THP1
72 macrophages even at 48h of LPS stimulation (Fig. 1C). The complete loss of LPS induced
73 expression in the presence of a TLR4 signaling inhibitor-CLI095, confirmed the dependence of
74 *CMPK2* expression on TLR4 signaling in macrophages (Fig. 1D). Further, macrophages
75 responded to *Salmonella enterica subsp. enterica serovar typhimurium* (STM) infection, by early
76 induction of *CMPK2* expression with 15-16 -fold increase by 3h wherein escalated further to ~30
77 fold by 6h of infection (Fig. 1E) and this response was completely abolished with the addition of

78 CLI095 confirming the TLR4 dependent expression of this gene in macrophages (Fig. 1F). A
 79 decrease in expression by more than 50% was observed in the case of macrophages infected
 80 with Mtb and treated with CLI095 again supporting the importance of TLR4 signaling in *CMPK2*
 81 expression (Fig. S1).

82
83
84
85
86



87
88
89
90
91

Fig. 1

92
93 **Fig. 1: CMPK2 expression in macrophages following stimulation.**

94 [A-F] Analysis of CMPK2 expression in THP1 macrophages following: infection with Mtb at a MOI of 5 [A],
 95 stimulation with various TLR ligands- c: Untreated cells, L: LPS (10 ng/ml), P: Pam3CSK4 (20 ng/ml), Z:
 96 Zymosan (10 µg/ml), I: Poly I:C (2 µg/ml) [B], LPS stimulation by immunoblotting with CMPK2-specific
 97 antibody [C], LPS stimulation with and without TLR4 inhibitor CLI095 [D], infection with STM [E], infection
 98 with STM in the presence of CLI095 [F]. Expression of *CMPK2* was quantitated by qPCR. Values are
 99 normalized with *GAPDH* and mean fold change compared to control cells \pm SEM from N=2/ 3 independent
 100 experiments.

101 **Modulation of CMPK2 activity affects the inflammation status of macrophages.**

102 In order to decode the molecular function of CMPK2 in the macrophage response, we used
 103 *CMPK2* specific siRNAs (a-c) to specifically silence this gene in THP1 cells (CM) and achieved

104 60-75% decrease in gene expression in comparison to scrambled siRNA (SC) (Fig. S2A). Only
105 siRNA-c showed a significant dip in protein levels in excess of 40% of the native CMPK2
106 expression and was used for further analysis (Fig. 2A). Given a critical role of proinflammatory
107 cytokines in macrophage response to infection, we compared the levels of TNF α and IL1 β in the
108 SC and CM macrophages in response to Mtb infection. Mtb infection induced *TNF α* and *IL1 β*
109 expression by 100-150- fold in CM macrophages while these levels were 3-4- fold lower in the
110 case of SC macrophages (Fig. 2B). Interestingly, expression levels of these genes were markedly
111 elevated in the uninfected cells. This pattern was also reflected by the enhanced expression levels
112 of other immune effectors like *IL8*, *IP10*, *VEGF* and decrease in *IL10* in naïve CM macrophages
113 strongly alluding to an enhanced pro- inflammatory status of these cells even in the resting state
114 (Fig. 2C). This profile of increased *TNF α* and *IL1 β* gene expression was observed in CM cells
115 following LPS stimulation (Fig. S2B). This enhanced expression also correlated well with the
116 increase in secreted TNF α and IL1 β in the culture supernatant of LPS treated CM cells (Fig. 2D).
117 Again, correlating with gene expression, naïve CM cells also secreted increased amounts of both
118 TNF α and IL1 β in the supernatants as compared to the non- detectable levels of the cytokine in
119 naïve SC macrophages.

120 Given the inflammatory phenotype observed with decreased CMPK2 expression in THP1
121 macrophages, we attempted to reverse this by complementing a functional copy of the gene in
122 the silenced cells. We expressed the complete CMPK2 as a mCherry fusion protein in pCDNA3.1
123 and analyzed the basal expression levels of *IL1 β* and *TNF α* . As expected, *CMPK2* expression
124 was ~30 folds higher levels than in empty vector control THP1 cells (Fig. 2E). Contrary to our
125 expectations, this enhanced expression of the *CMPK2* could not reverse the alteration in basal
126 inflammation of these cells: nearly similar levels of *IL1 β* and *TNF α* was observed in the
127 complemented cells as in the silenced cells (Fig. 2F). We hypothesized that similar to the situation
128 with CMPK2 silenced cells, increase in expression of CMPK2 was also detrimental to the
129 inflammation homeostasis of macrophages. To test this, we analyzed the pro inflammatory status

130 of THP1 cells stably expressing CMPK2-mCherry. Enhanced expression of *CMPK2* transcript in
131 excess of 100- fold basal levels was observed in the over expressing (OE) cells (Fig. S2C). The
132 fusion protein of CMPK2 and mCherry was also clearly detected in protein extracts of the OE
133 strains by immunoblotting (Fig. S2D). Again, this enhanced expression of CMPK2 resulted in
134 heightened levels of *TNF α* (12-15- fold) and *IL1 β* (100-150- fold) in OE cells (Fig. 2G).

135 In an effort to understand the basis for the hyper-inflammatory state of CM and OE cells, we
136 compared the immune signaling cascades of these cells with the respective controls in the basal
137 state. Consistently, we observed enhanced activation of ERK and NF κ B with 3-fold higher level
138 of phospho-p42-44 ERK and p65 NF κ B (Fig. 2H, S2E) without any change in p- JNK and p38
139 MAP kinase in CM cells compared to SC cells (Fig. S2F). This pattern of enhanced ERK
140 phosphorylation was also observed in the case of OE cells in comparison to VC cells. The use of
141 an ERK signaling specific inhibitor U0126 not only reduced the levels of p42-44-ERK in both the
142 CM and OE cells (Fig. 2I), but also significantly reduced the elevated levels of both *IL1 β* and *TNF α*
143 in both these cell types, further confirming the importance of ERK signaling in mediating the hyper
144 inflammatory phenotype of these macrophages (Fig. 2J, 2K).

145 Human mitochondrial CMPK2 has been shown to be a nucleotide kinase involved in mitochondrial
146 DNA synthesis (Fig. 2L). In an effort to probe the importance of the kinase domain, we substituted
147 the active site aspartate to alanine (D330A) as a kinase dead variant of CMPK2 (D330A) and
148 analyzed the functional consequence of this expression on cytokine gene expression. Despite the
149 strong and stable expression of D330A, comparable to the Wt CMPK2 (OE), both at the transcript
150 (Fig. S2G) and protein (Fig. 2L) level, there was no evidence of increased basal inflammation.
151 Contrasting with the significantly elevated levels of *TNF α* and *IL1 β* in the OE cells (~10 and ~80
152 fold, respectively over basal levels), THP1 cells transfected with D330A, harbored normal levels
153 of gene expression (Fig. 2M) emphasizing the importance of the kinase activity of CMPK2 in
154 regulating basal inflammation in macrophages.

155




Fig. 2

156 **Fig. 2: CMPK2 regulates the basal inflammation of macrophages.**

157 [A] Expression of CMPK2 in CMPK2 silenced macrophages by immunoblotting with specific antibodies. For
 158 immunoblotting, the expression of α -TUBULIN was used as control. One representative blot of 3
 159 independent experiments is shown. The levels of CMPK2 expression are depicted as mean fold change \pm
 160 SEM of N=3 experiments by densitometry. [B] Expression of the *IL1 β* and *TNF α* transcripts following
 161 infection with Mtb for 6h was evaluated in SC or CM macrophages by qPCR. [C] Basal level expression of
 162 transcripts *CMPK2* and cytokine genes in CM macrophages was estimated by qPCR with specific primers.
 163 Values are normalized with GAPDH and mean fold change compared to control cells \pm SEM from N=3

164 independent experiments. [D] Levels of $TNF\alpha$ and $IL1\beta$ in the culture supernatants of THP1 stably
165 expressing scrambled (white bars) or siRNA specific to CMPK2 (grey bars) estimated by ELISA. Values
166 are represented as mean pg/ml of the cytokine in triplicate assays from N=3 experiments. E] Expression of
167 *CMPK2* in the CMPK2 silenced cells with stable expression of CMPK2 (CM-OE) or empty vector (CM-VC).
168 The levels in the corresponding SC and CM cells are also shown. Values are represented as mean \pm SEM
169 of the triplicate assays from N=3 experiments. F] Expression of *TNF α* and *IL1 β* in the CMPK2 silenced cells
170 with stable expression of CMPK2 (CM-OE) or empty vector (CM-VC). The levels in the corresponding SC
171 and CM cells are also shown. Values are represented as mean \pm SEM of the triplicate assays from N=3
172 experiments. G] Expression of *TNF α* and *IL1 β* in THP1 cells after stable expression of CMPK2. Values are
173 represented as mean \pm SEM of the triplicate assays from N=3 experiments. H] Analysis of activation of the
174 ERK (p42/44) and NF κ B (p65) signaling pathways in SC, CM, VC and OE macrophages by immunoblotting
175 with antibodies specific for the phosphorylated (active) and non- phosphorylated forms of the proteins.
176 Representative blot of one experiment out of 3 individual assays is shown. Expression of α -TUBULIN was
177 used as control. I] ERK phosphorylation in macrophages with and without treatment with ERK specific
178 inhibitor U0126. Antibodies specific for the phosphorylated (active) and non- phosphorylated forms of the
179 proteins were used to probe cell extracts. Expression of α -TUBULIN was used as control. Blots are
180 representative of two independent experiments. J-K] Expression of *IL1 β* (J) and *TNF α* (K) in the 4 types of
181 macrophages after treatment with U0126 was analyzed by qPCR. Cells left untreated were used as control.
182 The relative gene expression folds in triplicate assay wells are represented with respect to GAPDH as mean
183 \pm SEM for N=2. L] The schematic of mutated catalytic site also depicted (D330A). Immunoblot analysis of
184 CMPK2-mCherry fusion protein using antibody specific for mCherry protein in protein lysates of VC, OE
185 and D330A THP1 cells with mCherry specific antibody. GAPDH was used as control. M] Expression of
186 *TNF α* and *IL1 β* in THP1 cells after stable expression of vector alone (VC) full length CMPK2 (OE) and
187 catalytic mutant of CMPK2 (D330A). The relative gene expression folds in triplicate assay wells are
188 represented with respect to *GAPDH* as mean \pm SEM for N=4.

189 **Increased inflammation of CM macrophages is associated with altered mitochondria and**
190 **augmented ROS.**

191 We presumed that identifying the precise localization of CMPK2 would reveal clues to its
192 molecular role in inflammation and mitochondrial membrane dynamics. We first validated the
193 mitochondrial localization of CMPK2 by immunoblotting subcellular fractions. With previous
194 reports indicative of a mitochondrial localization of CMPK2²⁵ and our observation of a majority of
195 the protein in the mitochondrial fraction (Fig. 3A), we tested purified mitochondrial fractions to
196 pinpoint its location by standard biochemical and immunoblotting analyses. While treatment with
197 Proteinase K (removes the surface exposed proteins), completely removed the outer membrane
198 protein TOM20, nearly 30% of CMPK2 was present in the pellet fraction of intact mitochondria,
199 similar to that observed for the other mitochondrial membrane associated protein –TIM50 (Fig.
200 3B) suggesting its association with the outer membrane of mitochondria. Most of the matrix
201 protein- SOD2 remained in the pellet and was lost only with complete solubilization with Triton X-
202 100. The peripheral association of CMPK2 with the mitochondrial membrane was also revealed
203 by a relatively higher amount of CMPK2 in the soluble fraction of mitochondria treated with
204 Na₂CO₃ in contrast with the integral membrane protein- TOM20 (Fig. 3C).

205 We hypothesized that two distinct possibilities could account for the enhanced basal levels of
206 inflammation observed in the CM and OE lines - 1) enhanced expression at all times or 2) a
207 temporal activation of the signaling with delayed decay kinetics. To test this, we checked the
208 expression of IL1 β in the two cell lines during the monocyte to macrophage transition upon PMA
209 treatment. While the monocytes did not show any difference in IL1 β expression, activation with
210 PMA induced distinct profiles of IL1 β activation in the control (SC) or CMPK2 silenced (CM) cells.
211 A rapid increase in IL1 β within a day of activation (~700 fold) was followed by a steady decline by
212 72h of treatment further reaching basal levels by day 4 in the control cells (Fig. 3D). CMPK2
213 silenced macrophages, however, displayed a protracted response kinetics with a slower rise in
214 expression levels ~1.5-2 folds lower than control cells at 24 h of activation with PMA. Between
215 24h and 72h of treatment, the levels were 3-5 fold higher in CM with a delayed decline of the
216 levels to ~500 fold by day 4 and did not fall to basal levels even by day 5.

217 Macrophage inflammation is strongly associated with ROS activation. To check this, we compared
218 the levels of mitochondrial ROS in SC and CM macrophages by using a ROS specific stain-
219 MitoSOX Red. Mitotracker deep red was used as control for the levels of mitochondria in the two
220 cell types. While similar levels of mitotracker staining hinted at unaltered mitochondrial levels, the
221 level of ROS (mitosox) was nearly 1.5-fold higher in CM cells as compared to control SC
222 macrophages (Fig. 3E). The importance of mito- ROS in enhanced inflammation in CM cells was
223 further evident when the cells were treated with a specific inhibitor- mitoquinone (MQ). Addition
224 of MQ early (immediately after PMA treatment) significantly reduced the expression of IL1 β in
225 these cells (Fig. 3F); use of MQ at later stages of differentiation (48h and 72h after PMA addition)
226 did not alter the inflammation in the CM cells (Fig. S3A, B). Mitochondrial membrane polarization
227 is a critical component of organelle integrity and physiology with alterations in membrane potential
228 leading to ROS in macrophages^{26, 27}. To test if the ROS was associated with change in membrane
229 potential, we compared the extent of TMRE staining (a dye that shows a potential dependent
230 differential partitioning across mitochondrial membranes) in the SC and CM cells. As seen in Fig.
231 3G, the mitochondria of CM macrophages exhibited significantly lower staining with TMRE, similar
232 to the SC cells treated with the proton pump uncoupler- CCCP, suggestive of a loss of membrane
233 integrity in the latter cells even at the basal level. CCCP further decreased the mitochondrial
234 membrane potential of the CM cells.

235 In order to test if the altered membrane potential affected mitochondrial architecture, we
236 compared the morphology of these organelles in the SC, CM, VC and OE cells. In sharp contrast
237 to the small uniformly distributed mitochondria in the control cells (SC and VC), larger and more
238 dense mitochondrial network was observed in the CM and OE cells (Fig. 3H, 3I). Mitochondrial
239 architecture and function is strongly dependent on the replication dynamics of these organelles.
240 Evaluation of the mitochondrial fission- fusion (replication) dynamics in the 4 cell types revealed
241 an important role for CMPK2 in regulating this process. Both in CM and OE cells, the levels of
242 DNM1L (crucial for mitochondrial fission) was expressed at 1/3rd the level observed in the SC and

243 VC cells (Fig. 3J) contrasting with an unaltered expression of the mitochondrial fusion associated
 244 proteins (MFN1 and OPA1) in these cells (Fig. S3C, S3D) implying the importance of optimal
 245 CMPK2 expression in mitochondrial physiology.




Fig. 3

246 **Fig. 3: Modulation of CMPK2 affects the mitochondrial physiology in macrophages.**

247 A] Expression of CMPK2 in subcellular fractions of THP1 macrophages by immunoblotting with specific
 248 antibodies, T- total cell extract, C- cytoplasmic fraction and M-Mitochondria. Expression of cytosolic protein
 249 α -TUBULIN and mitochondria resident protein VDAC are also represented. Blots are representative of three
 250 independent experiments. B] Mitochondrial fraction was subjected to Proteinase K treatment in the
 251 presence or absence of Triton X-100 and given osmotic shock (OS) and analyzed by immunoblotting. Data
 252 are representative of three independent experiments. C] Mitochondrial fraction was incubated with

253 mitochondrial buffer with and without Na_2CO_3 and centrifuged at 13,000 rpm for 15 min. The pellet (P) and
254 supernatant (S) fractions were immunoblotted. Data are representative of three independent experiments.
255 D) Kinetic profile of *IL1 β* expression in SC and CM during differentiation of monocytes to macrophages.
256 Expression was checked at different time intervals after PMA treatment. Values are mean fold change in
257 expression with respect to *GAPDH* \pm SEM triplicate assays of N=2 experiments. E) Analysis of
258 mitochondrial ROS in SC or CM macrophages. Cells were stained with MitoTracker Deep Red (as an
259 internal control) and ROS specific MitoSOX Red and specific population were quantified by FACS. The
260 histogram plots of a representative experiment of (N=4) is depicted. The extent of MitoSOX red mean
261 fluorescence intensity (MFI) \pm SEM is represented graphically in the inset. F) Expression of *IL1 β* in the
262 macrophages with the addition of a specific mitochondrial ROS inhibitor- MQ at day1 of PMA treatment was
263 analyzed by qPCR. Values are mean fold change in expression with respect to *GAPDH* \pm SEM for triplicate
264 assays of N=3 experiments. G] Analysis of mitochondrial membrane potential in SC or CM macrophages
265 by TMRE staining. Fluorescence values normalized to protein in samples is represented as mean
266 fluorescent intensity \pm SEM for triplicate assays of N=3 experiments. H, I] Mitochondrial architecture in
267 THP1 macrophages upon silencing CMPK2. Macrophages with control (SC) or CM [H] or VC or OE [I] was
268 analyzed by confocal microscopy. A representative image is depicted with the scale bar representing 10 μM ,
269 the region shown in higher magnification is depicted with the box. J] Expression of gene involved in
270 mitochondrial fission by immunoblotting with specific antibody. Expression of DNM1L is depicted along with
271 α -TUBULIN levels as a control. Relative intensity values are depicted as mean \pm SEM of N=3.

272 **Regulated levels of CMPK2 is critical for the normal metabolic activity of macrophages.**

273 In an attempt to understand the basis for this dysregulated inflammatory gene expression in both
274 the CM and OE macrophages, we performed global sequencing of transcripts and compared the
275 expression profiles with the control macrophages -SC and VC, respectively. Strikingly, again, on
276 comparison of the differentially expressed genes, inflammatory cytokine genes like *IL1 β* , *IL8*,
277 *TNF α* were commonly upregulated in both the CM and OE macrophages (Fig. 4A). This
278 consistency in gene expression profiles was also evident with the significantly large numbers of
279 genes increased (515) or decreased (500) in macrophages with abnormal CMPK2 expression

280 (Fig. 4A inset). A significant deregulation of basal level inflammation was also evident in Gene
281 Set Enrichment Analysis (GSEA) with heightened inflammation response as a key gene family
282 common to the two macrophage lines (Fig. 4B). Interestingly, enhanced expression of the hypoxia
283 genes combined with the higher inflammatory profile was reminiscent of M1 activated
284 macrophages. To validate this, we analyzed the expression profiles of previously identified
285 signatures of M1 and M2 polarized macrophages in our genesets²⁸. In agreement to our
286 hypothesis, both the CM and OE macrophages showed increase in the expression of genes of
287 M1 macrophages with a majority of the M2 specific signatures either unchanged or with reduced
288 expression levels (Fig. 4C). Further validation of a M1 bias was visible in the physiological state
289 of the cells. A deeper analysis revealed an increase in the expression of genes involved in
290 glycolysis (Fig. S4A, S4B) that manifested as a significant increase in the levels of glycolysis
291 intermediates like glucose / fructose 6-P, fructose bis-phosphates, DHAP, culminating in markedly
292 high levels of lactate (Fig. 4D). The associated decrease in genes and metabolites of the TCA
293 cycle was further supportive of a strong proinflammatory M1 like phenotype of both the CM and
294 OE macrophages. Moreover, both these cell types (CM and OE), displayed a significant reduction
295 in the NAD/ NADH ratios on account of significantly higher levels of NADH in the two cell types
296 with a 1.5-fold increase in net ATP levels in the CM cells (Figs. 4E, 5F). Further, analysis of
297 respiration rates of cells revealed a distinct pattern with a considerable dip in the oxygen
298 consumption rates of macrophages with altered expression of CMPK2. Both the CM and OE
299 macrophages displayed 2-2.5 folds lower oxygen consumption with delayed kinetics as opposed
300 to the control macrophages SC and VC (Fig. 4G, H) implicating a strong shift of macrophages
301 with altered CMPK2 expression towards a pro-inflammatory phenotype and the important role for
302 CMPK2 in maintaining homeostasis of macrophages.




Fig. 4

303 **Fig. 4: Macrophages with dysregulated CMPK2 display inflammation and metabolic signatures of**
 304 **activated M1 macrophages.**

305 A) Scatter plot of genes differentially expressed in CM or OE macrophages relative to the expression levels
306 in the control macrophages (SC or VC), respectively. Change in expression is depicted as \log_2 fold change
307 in expression. The number of genes up- and down- regulated in the macrophages are depicted as a Venn
308 diagram (inset). B) GSEA hallmark pathway enrichment analysis of the commonly up and down regulated
309 genes in the CM and OE macrophages are represented as a bubble plot. X axis is the number of genes of
310 the pathway and size of the bubble depicts significance ($-\log P$ value). C) The expression patterns of genes
311 specific to M1 and M2 activated macrophages in the CMPK2 dysregulated macrophages CM and OE are
312 represented as heat maps. The values represent \log_2 fold change from the corresponding control cells. D)
313 Metabolite levels in the CMPK2 silenced (CM) and over-expression (OE) and their respective control
314 macrophages were assayed from cellular extracts by MS. The levels of individual metabolites in the CM
315 and OE macrophages (represented in green) are represented as relative percent of the concentrations in
316 the respective control cells as mean \pm SEM from 3 independent experiments (N=3). E&F) The levels of
317 ATP (E), NAD, NADH (F) in the different macrophages was determined by MS. The relative levels of ATP
318 or the ratio of NAD and NADH are represented as mean values \pm SEM in the CMPK2 modulated cells with
319 respect to the control cells of N=3/2 experiments. G&H) Continual estimation of oxygen consumption in SC,
320 CM (G) and VC, OE (H) macrophages until 3h with Oroboros oxygraph. The level of oxygen consumption
321 was calculated and mean OCR values \pm SEM of N=3 experiments is shown in the inset.

322 **CMPK2 plays a critical role in the macrophage ability to control infection**

323 To understand the impact of altered CMPK2 expression in macrophage inflammatory properties,
324 we evaluated its ability to control intracellular growth of Mtb. We observed a 2-3 fold decrease in
325 intracellular bacterial numbers in these macrophages as compared to SC late in infection (day 5),
326 CM cells were able to control bacterial levels to input levels by this timepoint compared to growth
327 of about 5-6 folds in the SC macrophages (Fig. 5A). This pattern of increased bacterial control
328 was also evident in STM infected CM macrophages with 2-3 fold lower bacterial numbers after 24
329 h of infection (Fig. 5B).

330

331

332

333

334

335

336

337




Fig. 5

338 **Fig. 5: CMPK2 regulates bactericidal activity of macrophages**

339 A] Growth kinetics of Mtb in SC and CM macrophages at different times post infection at a MOI of 5 for 6h.

340 Values are mean CFU \pm SEM values in triplicate assays of N=4. [B] Growth kinetics of STM in SC and CM

341 macrophages at different times post infection at a MOI of 10 for 20 min. Values are mean CFU \pm SEM

342 values in triplicate assays of N=4.

343 **DISCUSSION**

344 Macrophages, the primary cells that sense and respond to any infectious agents or tissue

345 damage, are critical components of vertebrate innate immune responses. Being endowed with

346 the capacity to initiate and manifest strong infection control programs to a variety of pathogens,

347 they often dictate both acute and chronic outcomes of infection in the host^{29, 30}. Recent evidence

348 implicates these cells in maintenance of tissue homeostasis during steady state and

349 inflammation^{30, 31, 32, 33}. Apart from controlling the infection response, they are actively involved in

350 removal of cellular or bacterial debris to prevent long term inflammation^{33, 34, 35}. Several studies

351 have identified functionally distinct macrophage sets with polarized pro-inflammatory (M1) or anti-

352 inflammatory (M2) phenotypes with distinct metabolic characteristics^{36, 37, 38}. An important role for

353 mitochondrial dynamics and function is recognized in regulating host cell metabolism as well as

354 the response to infections^{39, 40}. Several stimuli or bacterial infections modulate mitochondrial

355 function in order to influence immune signaling^{10, 41, 42}. Contrasting with the glycolytic shift in

356 cellular metabolism in response to LPS stimulation or infection in the M1 polarized macrophages,

357 IL4 induced M2 macrophages predominantly rely on oxidative phosphorylation and fatty acid

358 oxidation for energy^{43, 44} thereby implicating the mitochondria in regulating macrophage
359 immunometabolism.

360 We provide evidence for an important role of the mitochondrial gene CMPK2 in regulating the
361 basal inflammation in human macrophages. CMPK2 has previously been identified as a dominant
362 component of macrophage anti-viral response to HIV, DENV, SVCV^{25, 45, 46, 47}. Recently, CMPK2
363 has been shown to be involved in regulating foam cell formation in atherosclerosis⁴⁸. Mouse
364 CMPK2 has been shown to be involved in the synthesis of mitochondrial DNA and is critical to
365 the formation of ox-mtDNA fragments in response to NLRP3 activation²⁴ implicating this gene in
366 regulation of innate immune response. However, the exact function of CMPK2 is still unclear. To
367 elucidate a role of CMPK2 in macrophage physiology, we tested the effect of CMPK2 silencing
368 as well as over expression and demonstrate gross changes in the inflammatory capacity, orienting
369 cellular metabolism towards rapid energy production via glycolysis to facilitate a pro-inflammatory
370 M1 phenotype in the macrophages. Macrophages with altered CMPK2 levels (CM and OE) show
371 consistent features of enhanced activation of ERK signaling leading to a marked increase in
372 production of pro-inflammatory mediators like TNF α , IL8, IL1 β dependent on the manifestation
373 of increased mitochondrial ROS.

374 These conditions mimic the strong induction of CMPK2 in macrophages following infection by
375 intracellular bacteria like STM or Mtb, thereby preparing cells for M1 polarization required for
376 infection control⁴⁹. Given our observation of similar phenotypes in both gene silenced and over
377 expression cells, it is logical to assume the association of CMPK2 in a larger protein complex in
378 cells⁵⁰. In support of this, we found this protein to localize to the mitochondrial membrane
379 suggesting its proximity to the mitochondrial ETC proteins. In fact, we also observed a decrease
380 in levels of complex 1 (Fig. S5), lending further credence to an impaired oxidative phosphorylation
381 in these cells. This was also supported by the severe impairment in oxygen consumption with a
382 concomitant increase of the glycolytic metabolite- lactate in the CM and OE macrophages.

383 Recently, lactate production by M1 polarized macrophages has been attributed to microbicidal
384 capacity of these cells against Mtb⁵¹.

385 We observed that removal of MLS from CMPK2 destabilized the protein and resulted in enhanced
386 degradation by the cellular proteolytic machinery. This observation is in sync with previous
387 reports⁵² demonstrating that mitochondrial proteins without signals for mitochondrial partitioning
388 tend to form mis-folded aggregates that are rapidly degraded by the host proteasome⁵³. We also
389 observed an absolute requirement of kinase activity for CMPK2 function and the importance of
390 the N- terminal DUF domain in protein stability (data not shown, part of another manuscript).

391 Given the importance of CMPK2 in maintaining mitochondrial architecture, function and in
392 enhancing overall inflammation, macrophage would actively induce this gene as a response to
393 intracellular bacterial infection. With bacterial contact immediately stimulating host cell surface
394 receptors, it is not surprising that CMPK2 would be induced in response to activation of more
395 central TLR4 signaling that primarily leads to activation of inflammatory programs in the infected
396 macrophages. Moreover, our data of a long-term breakdown of inflammation control in
397 macrophages following prolonged disturbance of CMPK2 expression levels only highlights the
398 importance of rapid and robust regulation of this gene by cells for reverting to basal status. This
399 supports our hypothesis that CMPK2 is an important component of the cellular inflammation
400 rheostat controlling macrophage metabolic and transcriptional response to infections. Pinpointing
401 the precise molecular mechanism of CMPK2 mediated regulation of macrophage immuno-
402 metabolism would help develop novel mechanisms of modulating innate response control paving
403 the way for future host cell directed therapeutics.

404

405

406

407

408 **Supplementary Figures:**

409

410

411

412

413

414

415

416

417




Fig. S1

418 **Fig. S1:** Expression of *CMPK2* in THP1 macrophages upon Mtb infection in the presence or absence of
419 CLI095.




Fig. S2

420 **Fig. S2:** A) Expression of *CMPK2* in THP1 macrophages stably expressing the scrambled (SC) siRNA or
421 three different siRNAs (a-c) against *CMPK2* by qPCR (B). The gene expression was normalized with
422 *GAPDH* and relative fold changes compared to SC are represented as mean \pm SEM (N=2). B) Expression
423 of *TNF α* and *IL1 β* gene in SC and CM macrophages following LPS stimulation for 6h. The relative gene
424 expression folds in triplicate assay wells are represented with respect to *GAPDH* as mean \pm SEM for N=2.

425 C] Expression of *CMPK2* in OE or empty vector -VC cells was analyzed by qPCR. The relative gene
 426 expression folds in triplicate assay wells are represented with respect to *GAPDH* as mean \pm SEM for N=3.
 427 D] *CMPK2* expression in VC and OE cells were analyzed by immunoblotting with tag specific (mCherry)
 428 antibody. E] Relative quantitation of p-ERK and p-NF κ B in the SC, CM, VC, OE cells by densitometric
 429 analysis of immunoreactivity is shown. Values are mean + SEM of triplicate (N=3) independent blots. F]
 430 Analysis of activation of the p38 MAPK and SAPK/JNK signaling pathways in SC and CM macrophages by
 431 immunoblotting with antibodies specific for the phosphorylated (active) and non- phosphorylated forms of
 432 the proteins. The relative intensities of the blots in the *CMPK2* silenced cells w.r.t control (SC) cells are
 433 represented as mean \pm SEM of N=3. Expression of α -TUBULIN was used as control. G] Expression of
 434 *CMPK2* in VC, OE and D330A cells was analyzed by qPCR and is depicted relative to *GAPDH* levels of
 435 N=3 assays.




Fig. S3

436 **Fig. S3:** A, B] Expression of *IL1β* in the macrophages with the addition of a specific mitochondrial ROS
 437 inhibitor- MQ at day 2 [A] and day 3 [B] of PMA treatment intervals post activation was analyzed by qPCR.
 438 Values are mean fold change in expression with respect to *GAPDH* \pm SEM for triplicate assays of N=2/3
 439 experiments. C, D] Expression of proteins involved in mitochondrial fusion by immunoblotting with specific
 440 antibodies. MFN1&2 and OPA1 were checked in SC, CM [C] or VC, OE [D] cells along with α -TUBULIN
 441 levels as a control. Relative intensity values are depicted \pm SEM of N=3.

442
 443
 444




Fig. S4

455 **Fig. S4:** A] Expression of genes involved in glycolysis and TCA were represented as heatmap. The
 456 expression was extracted from the RNA sequencing data of CMPK2 dysregulated THP1 cell. The values
 457 are represented as log₂ compared to respective control cells. B-D] Expression of *HK2* [B],
 458 *ENO2* [D] was validated by qPCR with specific primers. Values are represented are relative to *GAPDH*
 459 expression in the SC, CM, VC and OE cells of N=3 independent assays of triplicate wells.




Fig. S5

465 **Fig. S5:** Analysis of expression of protein complexes of the mitochondrial respiratory chain in cell lysates
 466 of SC and CM macrophages by immunoblotting. α -TUBULIN (T) and VDAC1 (VD) were used as loading
 467 controls. The band intensities of the complex proteins were normalized to α -TUBULIN and the relative
 468 intensity of CM w.r.t. SC is represented as fold change \pm SEM for N=2.

469
 470
 471

472 **Material and Methods**

473 **Reagents**

474 The following chemicals were purchased from Sigma-Aldrich: U0126 (U120), RNAzol RT
475 (R4533), Zymosan (Z4250), Thermo Fisher Scientific: MitoSOX Red (M36008), MitoTracker Deep
476 Red (M22426) and Invivogen: LPS (tlrl-smlps), CLI095 (tlrl-cli095), poly I:C (tlrl-pic), Pam3CSK4
477 (tlrl-pms). Mitoquinol (89950) was purchased from Cayman Chemical Company.

478 **Cell culture**

479 THP-1 cells were cultured in RPMI-1640 (Himedia laboratories, Mumbai, India) media
480 supplemented with 10% FBS and 1mM sodium pyruvate (Himedia laboratories, Mumbai, India).
481 HEK293T cells were cultured in DMEM supplemented with 10% FBS and 1mM sodium pyruvate.
482 For differentiation, THP-1 cells were treated with 100nM PMA for 24hr and rested for 48hr before
483 the next manipulation. Both cell lines were confirmed for their identity by STR PCR analysis and
484 maintained mycoplasma free by routine checking.

485 **Generation of THP1 lines with CMPK2 silencing**

486 To generate knockdown cells, HEK293T cells were co-transfected with CMPK2 siRNA plasmid
487 (Applied Biological Materials Inc, Richmond, Canada), packaging plasmid (pCMV-dR8.2) and
488 envelope plasmid (pCMV-VSV-G) using Lipofectamine-LTX reagent (Thermo Fisher Scientific
489 India Pvt. Ltd, Mumbai, India). After 6h of transfection, media removed and fresh media was
490 added to the cells. After 48h of transfection, the culture supernatant was collected, centrifuged at
491 500 rpm to remove cell debris. The virus particles in the supernatant were concentrated to 100 μ l
492 using Amicon® Ultra-15 Centrifugal Filters (Sigma-Aldrich Chemicals Private Limited, Bengaluru,
493 India) and used to infect THP1 cells. Cells were then selected with 0.6 μ g/ml puromycin and GFP
494 positive clones were used for further studies.

495 **Bacterial culturing and infection**

496 *Mycobacterium tuberculosis* strain Erdman was grown in 7H9 Middlebrook media BD
497 Biosciences, USA) supplemented with Middlebrook ADC (BD, USA) at 37°C. *E. coli* and

498 *Salmonella enterica* serovar *Typhimurium* were grown in Luria-Bertani (LB) media (Himedia
499 Laboratories, Mumbai, India) at 37°C. Single cell suspension of mid-log phase bacteria was
500 adjusted to the required cell density and then used to infect the differentiated THP-1 macrophages
501 at multiplicity of infection (MOI) of 5. After 6h *p.i.* for Mtb, cells were washed with PBS to remove
502 extracellular bacteria, and at various times post infection, bacterial numbers were enumerated by
503 lysis of cells and plating for CFU in 7H10 agar plates. For *S. typhimurium/ E. coli*, post addition of
504 bacteria at a MOI of 10, the plates were centrifuged for 5 min and then left for 20 min at 37°C. The
505 media removed and treated with 100µg/ml of gentamicin for 2h in RPMI at 37°C. The cells were
506 washed with PBS for 3 times, and infection was continued in media containing 12µg/ml of
507 gentamicin and at indicated time points cells were lysed with PBS-Triton-X-100 (1%) for CFU
508 plating on LB agar (Himedia laboratories, Mumbai, India) plates. The colonies were counted and
509 is represented as CFU/well.

510 **Gene expression analysis by qPCR**

511 Total RNA was isolated using RNAzol (Sigma-Aldrich, USA) method and the concentration was
512 quantified using Nanodrop 2000 UV-visible spectrophotometer. cDNA was prepared with 250-
513 1000 ng total RNA by a RT-PCR using Verso cDNA synthesis kit (Thermo Fisher Scientific, USA).
514 qPCR was performed on a Roche LC480 II system using DyNAmo Flash SYBR Green mix
515 (Thermo Fisher Scientific, USA). Primer sequences are given in Table 1.

516 **Cloning of CMPK2 and the D330 variant.**

517 The NFκB promoter from pNFκB-d2GFP was excised by digestion with *Ecl136II* and *HindIII* and
518 the mCherry fragment from pmCherry-N1 was removed with *HindIII* and *HpaI* and ligated to *NruI*
519 and *EcoRV* digested pcDNA3.1(+) to get the plasmid pPRAM1. The NFκB promoter from
520 pPRAM1 was replaced with EF-1α from pTracer-EF/V5 His A by using *MluI* and *EcoRI* to get
521 pPRAM2. The CMPK2 fragments were amplified from THP1 cDNA using the primer sets PP1 and
522 PP2 and cloned into the pPRAM2 using *KpnI* and *BamHI*. The D330A catalytic site mutant was

523 prepared by site directed mutagenesis using the primers PP3 and PP4. The sequences were
524 verified by sequencing. The list of primers used in this study is given in table 1.

525 **Western blotting and ELISA**

526 For immunoblotting, cells were lysed in RIPA buffer, resolved by SDS-PAGE and transferred to
527 nitrocellulose membrane. After blocking with 5% BSA in Tris Buffered Saline Tween (TBST) for
528 1hr at room temperature, membranes were incubated with the appropriate dilution of the primary
529 antibody overnight, washed with PBS and probed with infra- red dye conjugated secondary
530 antibody and developed in the LI-COR Odyssey platform. The following antibodies were
531 purchased from Cell Signaling Technology: Rabbit anti- α -tubulin (2125), Rabbit anti-phospho-
532 p42/44 (4377), Rabbit anti-p42/44 (4695), Rabbit anti-phospho-NF κ B p65 (3033), Rabbit anti-
533 NF κ B p65 (4764), Rabbit anti-phospho-JNK (4671), Rabbit anti-JNK (9258), Abcam: Rabbit anti-
534 mCherry (ab167453), Mouse anti-TOM20 (ab56783), Rabbit anti-TIM50 (ab109436), Mouse anti-
535 MFN1/2 (ab57602), Mouse anti-OPA1 (ab194830), Rabbit anti-DRP1 (ab140494), BD
536 Bioscience: Rabbit anti-VDAC (D73D12), Mouse anti-SOD2 (611581) and LI-COR Biotechnology:
537 Goat anti-Rabbit IgG 800 (926-32211), Goat anti-Mouse IgG 680 (926-68070). Rabbit anti-
538 CMPK2 (HPA041430) was purchased from Sigma-Aldrich.

539 For ELISA, either cell supernatants or cell extracts were used for cytokine estimation with specific
540 kits- TNF α (cat no: 88-7346-77, eBioscience) and IL1 β (cat no: 557953, BD Biosciences) ELISA
541 kits according to manufacturer's protocol.

542 **Analysis of ROS by FACS**

543 THP1 monocyte derived macrophages (MDM) were removed with PBS and 4mM EDTA, washed
544 with PBS, resuspended in RPMI media and used for staining with 5 μ M MitoSOX Red and 100nM
545 MitoTracker Deep Red at 37°C for 30 mins. Cells were then washed twice in HBSS and finally
546 resuspended in 500 μ l HBSS and analyzed in FACS ARIA II (BD Biosciences).

547 **Metabolite measurement**

548 Intracellular metabolites for MS-based targeted metabolomics were extracted using methanol-
549 water. Briefly, 1.2×10^6 cells from each condition were washed three times with ice-cold PBS, and
550 then quenched with methanol-water (4:1). The cell suspension was freeze thawed in liquid
551 nitrogen for three times. The suspension was centrifuged at 15,000 g at 4°C for 10 min.
552 Supernatant was collected, vacuum dried and then reconstituted in 50 μ l of 50% methanol. The
553 reconstituted mixture was centrifuged at 15,000 g for 10 min, and 5 μ l was injected for LC–MS/MS
554 analysis.

555 The data were acquired using a Sciex Exion LCTM analytical UHPLC system coupled with a triple
556 quadrupole hybrid ion trap mass spectrometer (QTrap 6500; Sciex) in negative ion mode.
557 Samples were loaded onto an Acquity UPLC BEH HILIC (1.7 μ m, 2.1 \times 100 mm) column, with a
558 flow rate of 0.3 ml/min. The mobile phases comprising of 10 mM ammonium acetate and 0.1%
559 formic acid (buffer A) and 95% acetonitrile with 5 mM ammonium acetate and 0.1% formic acid
560 (buffer B). The linear mobile phase was applied from 95% to 20% of buffer A. The gradient
561 program was used as follows: 95% buffer B for 1.5 min, 80%–50% buffer B in next 0.5 min,
562 followed by 50% buffer B for next 2 min, and then decreased to 20% buffer B in next 50 s, 20%
563 buffer B for next 2 min, and finally again 95% buffer B for next 2 min. After data acquisition, peaks
564 corresponding to each metabolite were extracted using Sciex MultiQuant TM v.3.0 software and
565 the area were exported in an excel sheet. Normalization was performed using total area sum of
566 that particular run.

567 **Oxygen Consumption**

568 $3\text{--}4 \times 10^6$ cells of THP1 MDMs in complete RPMI were added to the chambers of the Oxygraphy-
569 2k (O2k, Oroboros Instruments, Innsbruck, Austria). The oxygen concentration was measured
570 over time at 37°C under constant stirring. The oxygen consumption rate was calculated using XY
571 graph of oxygen consumption and time.

572 **Transcriptome analysis**

573 Total RNA isolated using RNAzol (Sigma Aldrich, India) and transcript sequencing was done
574 commercially by Bencos research solutions private ltd., (Bengaluru, India). cDNA libraries were
575 generated using Truseq RNA Library Prep Kit (Illumina San Diego, USA) and sequenced in a
576 Illumina Novaseq 6000 platform. RNA-seq reads were aligned with hg38 genome using STAR
577 ⁵⁴. HTseq-count was used to count the transcripts ⁵⁵. The differential expression analysis across
578 samples were analyzed using GSEA ⁵⁶.

579 **Confocal Microscopy and Image analysis of stained cells**

580 THP1 monocytes (stably transfectants of scrambled or CMPK2 specific siRNA) were transfected
581 with plasmid DNA mtDsRed (kind gift by Dr. Sowmya Sinha Roy, CSIR- IGIB) and selected for
582 stably expressing clones with 400µg/ml of G418. Cells were differentiated on coverslips, fixed
583 with 4% formaldehyde and imaged in a Leica 480 confocal microscopy. For live imaging,
584 monocytes overexpressing CMPK2 were plated at a cell density of 0.3×10^6 cells/ml in the cell
585 culture dish containing two chambers per dish (1 ml/ chamber). Mitotracker Green dye was added
586 to the media and the cells were kept in 37°C CO₂ incubator for 20mins. The cells were imaged on
587 a Leica SP8 confocal microscope.

588 **Mitochondrial localization**

589 Differential centrifugation was employed for mitochondria isolation from the cells ⁵⁷. Briefly, $2.5 \times$
590 10^6 THP1 MDMs were washed twice with PBS and resuspended in 3 ml ice-cold cell isolation
591 buffer (IBc- containing 10mM Tris pH to 7.4, 1mM EGTA pH to 7.4 and 0.2M sucrose). The cells
592 were homogenized using a glass Teflon pestle potter. The homogenate was then centrifuged at
593 600g for 10 min at 4°C, supernatant was collected and centrifuged at 7000g for 10 min at 4°C.
594 The pellet was then washed and resuspended in 200 µl IB_c and transferred to a 1.5ml Eppendorf
595 tubes. The homogenate was again centrifuged at 7000g for 10 min at 4°C. The supernatant was
596 discarded and the pellet was resuspended to get the mitochondrial fraction.

597 For Proteinase K digestion, the mitochondria were resuspended in MS buffer (210mM mannitol,
598 70mM sucrose, 5mM Tris-HCL-pH 7.5, 1mM EDTA-pH 7.6)/ 20mMHEPES with or without 2

599 mg/ml Proteinase K (for 15 min) and/or 1% Triton-X-100. The reaction was terminated by addition
600 of 5 mM phenylmethylsulfonyl fluoride. The mixture was centrifuged at 15000g for 15 min and the
601 pellet fraction was collected. For analysis of membrane proteins, the mitochondrial fraction was
602 resuspended in MS buffer with and without 0.1M Na₂CO₃ and incubated in ice for 30 min. The
603 pellet and supernatant fractions were collected 15000g for 15 min. All fraction were analyzed by
604 immunoblotting with respective antibodies.

605 **Graphs and Statistical analysis**

606 Statistical analyses were performed by using the two tailed Student's t-test. GraphPad Prism
607 software was used for graphs and statistical analysis.

608 **Table 1: List of primers used in this study**

Name	Primer sequence
CMPK2 F	CCAGGTTGTTGCCATCGAAG
CMPK2 R	CAAGAGGGTGGTGACTTTAAGAG
IL8 F	AGACAGCAGAGCACACAAGC
IL8 R	ATGGTTCCTTCCGGTGGT
GAPDH F	GAAGGTGAAGGTCGGAGTC
GAPDH R	GAAGATGGTGATGGGATTTC
IL1 β F	CCTGTCCTGCGTGTTGAAAGA
IL1 β R	GGGAACTGGGCAGACTCAAA
TNF α F	CCCAGGGACCTCTCTAATC
TNF α R	GGTTTGCTACAACATGGGCTACA
IP10 F	TCCACGTGTTGAGATCATTGC
IP10 R	GGCCTTCGATTCTGGATTGAG
IL10 F	GCTGGAGGACTTTAAGGGTTACCT
IL10 R	CTTGATGTCTGGGTCTTGTTCT
VEGF α F	CTGCTGTCTTGGGTGCATTG
VEGF α R	CCATGAACTTCACCACTTCG
PP1	ATGGTACCATGGCCTTCGCCCGCCGGCTC
PP2	CGTCTAGAGGATCCGCCGGTTCACTAAACTATTCTGG
PP3	CAAATCTCCTGTGATTGTAGCCAGGTAAGGACAGCAC
PP4	GTGCTGTGCCAGTACCTGGCTACAATCACAGGAGATTG

609
610 **Acknowledgements:** The authors thank CSIR (VR-BSC0123, MLP2012), and DBT (SG-
611 GAP0088) funding agency for supporting the study. The authors thank Mr. Manish Kumar and

612 CSIR- BSC0403 for the confocal microscopy facility, CSIR-STS0016 for BSL3 facility. The authors
613 wish to thank Dr. Sowmya Sinha Roy, CSIR-IGIB for the plasmid pmtDsRed. The authors thank
614 PA's doctoral advisory committee members for useful discussions and comments on the project.
615 The mass spectrometry facilities are duly acknowledged. The student fellowships from CSIR: PA-
616 CSIR- SRF, RA, PA- CSIR-BSC0124, MC- CSIR-JRF, India.

617 **Author Contributions:** PA, SR, SG, and VR were involved in conceptualizing and design of the
618 work. Experiments was performed by PA, MC, TR and DS. PA and RC performed Mass
619 spectrometry, PA, SG, and VR wrote the manuscript.

620 **Conflict of interest:** The authors do not have any competing interests.

621 **References**

- 622 1. Labbe K, Murley A, Nunnari J. Determinants and functions of mitochondrial behavior. *Annu Rev*
623 *Cell Dev Biol* **30**, 357-391 (2014).
- 624 2. Picard M, McEwen BS. Psychological Stress and Mitochondria: A Conceptual Framework.
625 *Psychosom Med* **80**, 126-140 (2018).
- 626 3. Weinberg SE, Sena LA, Chandel NS. Mitochondria in the regulation of innate and adaptive
627 immunity. *Immunity* **42**, 406-417 (2015).
- 628 4. Rambold AS, Pearce EL. Mitochondrial Dynamics at the Interface of Immune Cell Metabolism and
629 Function. *Trends Immunol* **39**, 6-18 (2018).
- 630 5. Kikuchi Y, Miyauchi M, Iwano I, Kita T, Oomori K, Kizawa I. Adjuvant effects of prostaglandin D2 to
631 cisplatin on human ovarian cancer cell growth in nude mice. *Eur J Cancer Clin Oncol* **24**, 1829-1833
632 (1988).
- 633 6. Newsholme P, Curi R, Gordon S, Newsholme EA. Metabolism of glucose, glutamine, long-chain
634 fatty acids and ketone bodies by murine macrophages. *Biochem J* **239**, 121-125 (1986).
- 635 7. Blagih J, Jones RG. Polarizing macrophages through reprogramming of glucose metabolism. *Cell*
636 *Metab* **15**, 793-795 (2012).
- 637 8. Rodriguez-Prados JC, *et al.* Substrate fate in activated macrophages: a comparison between
638 innate, classic, and alternative activation. *J Immunol* **185**, 605-614 (2010).
- 639
- 640
- 641
- 642
- 643
- 644
- 645

- 646
647 9. Viola A, Munari F, Sanchez-Rodriguez R, Scolaro T, Castegna A. The Metabolic Signature of
648 Macrophage Responses. *Front Immunol* **10**, 1462 (2019).
- 649
650 10. Mills EL, *et al.* Succinate Dehydrogenase Supports Metabolic Repurposing of Mitochondria to
651 Drive Inflammatory Macrophages. *Cell* **167**, 457-470 e413 (2016).
- 652
653 11. Van den Bossche J, *et al.* Mitochondrial Dysfunction Prevents Repolarization of Inflammatory
654 Macrophages. *Cell Rep* **17**, 684-696 (2016).
- 655
656 12. Kelly B, O'Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate
657 immunity. *Cell Res* **25**, 771-784 (2015).
- 658
659 13. Labadarios D, *et al.* Vitamin A in acne vulgaris. *Clin Exp Dermatol* **12**, 432-436 (1987).
- 660
661 14. Cohen HB, Mosser DM. Extrinsic and intrinsic control of macrophage inflammatory responses. *J*
662 *Leukoc Biol* **94**, 913-919 (2013).
- 663
664 15. Yan J, Horng T. Lipid Metabolism in Regulation of Macrophage Functions. *Trends Cell Biol* **30**, 979-
665 989 (2020).
- 666
667 16. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity
668 with identity. *Nat Rev Immunol* **11**, 750-761 (2011).
- 669
670 17. Sugimoto MA, Sousa LP, Pinho V, Perretti M, Teixeira MM. Resolution of Inflammation: What
671 Controls Its Onset? *Front Immunol* **7**, 160 (2016).
- 672
673 18. Missiroli S, Genovese I, Perrone M, Vezzani B, Vitto VAM, Giorgi C. The Role of Mitochondria in
674 Inflammation: From Cancer to Neurodegenerative Disorders. *J Clin Med* **9**, (2020).
- 675
676 19. Tiku V, Tan MW, Dikic I. Mitochondrial Functions in Infection and Immunity. *Trends Cell Biol* **30**,
677 263-275 (2020).
- 678
679 20. Wang Y, Li N, Zhang X, Horng T. Mitochondrial metabolism regulates macrophage biology. *J Biol*
680 *Chem* **297**, 100904 (2021).
- 681
682 21. Boxx GM, Cheng G. The Roles of Type I Interferon in Bacterial Infection. *Cell Host Microbe* **19**, 760-
683 769 (2016).
- 684

- 685 22. McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease. *Nat*
686 *Rev Immunol* **15**, 87-103 (2015).
- 687
- 688 23. Kovarik P, Castiglia V, Ivin M, Ebner F. Type I Interferons in Bacterial Infections: A Balancing Act.
689 *Front Immunol* **7**, 652 (2016).
- 690
- 691 24. Zhong Z, *et al.* New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. *Nature*
692 **560**, 198-203 (2018).
- 693
- 694 25. Xu Y, Johansson M, Karlsson A. Human UMP-CMP kinase 2, a novel nucleoside monophosphate
695 kinase localized in mitochondria. *J Biol Chem* **283**, 1563-1571 (2008).
- 696
- 697 26. Suski JM, Lebiezinska M, Bonora M, Pinton P, Duszynski J, Wieckowski MR. Relation between
698 mitochondrial membrane potential and ROS formation. *Methods Mol Biol* **810**, 183-205 (2012).
- 699
- 700 27. Vysokikh MY, *et al.* Mild depolarization of the inner mitochondrial membrane is a crucial
701 component of an anti-aging program. *Proc Natl Acad Sci U S A* **117**, 6491-6501 (2020).
- 702
- 703 28. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-
704 to-macrophage differentiation and polarization: new molecules and patterns of gene expression.
705 *J Immunol* **177**, 7303-7311 (2006).
- 706
- 707 29. Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory
708 diseases. *Nat Rev Immunol* **20**, 95-112 (2020).
- 709
- 710 30. Mosser DM, Hamidzadeh K, Goncalves R. Macrophages and the maintenance of homeostasis. *Cell*
711 *Mol Immunol* **18**, 579-587 (2021).
- 712
- 713 31. Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease. *Nat Rev Immunol* **17**,
714 306-321 (2017).
- 715
- 716 32. Watanabe S, Alexander M, Misharin AV, Budinger GRS. The role of macrophages in the resolution
717 of inflammation. *J Clin Invest* **129**, 2619-2628 (2019).
- 718
- 719 33. Oishi Y, Manabe I. Macrophages in inflammation, repair and regeneration. *Int Immunol* **30**, 511-
720 528 (2018).
- 721
- 722 34. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease.
723 *Nature* **496**, 445-455 (2013).
- 724

- 725 35. Lavin Y, Mortha A, Rahman A, Merad M. Regulation of macrophage development and function in
726 peripheral tissues. *Nat Rev Immunol* **15**, 731-744 (2015).
- 727
- 728 36. Galvan-Pena S, O'Neill LA. Metabolic reprogramming in macrophage polarization. *Front Immunol* **5**,
729 420 (2014).
- 730
- 731 37. Tan Z, *et al.* Pyruvate dehydrogenase kinase 1 participates in macrophage polarization via
732 regulating glucose metabolism. *J Immunol* **194**, 6082-6089 (2015).
- 733
- 734 38. Wang F, *et al.* Glycolytic Stimulation Is Not a Requirement for M2 Macrophage Differentiation.
735 *Cell Metab* **28**, 463-475 e464 (2018).
- 736
- 737 39. Mehta MM, Weinberg SE, Chandel NS. Mitochondrial control of immunity: beyond ATP. *Nat Rev*
738 *Immunol* **17**, 608-620 (2017).
- 739
- 740 40. Benmoussa K, Garaude J, Acin-Perez R. How Mitochondrial Metabolism Contributes to
741 Macrophage Phenotype and Functions. *J Mol Biol* **430**, 3906-3921 (2018).
- 742
- 743 41. Ramond E, Jamet A, Coureuil M, Charbit A. Pivotal Role of Mitochondria in Macrophage Response
744 to Bacterial Pathogens. *Front Immunol* **10**, 2461 (2019).
- 745
- 746 42. Ubanako P, Xelwa N, Ntwasa M. LPS induces inflammatory chemokines via TLR-4 signalling and
747 enhances the Warburg Effect in THP-1 cells. *PLoS One* **14**, e0222614 (2019).
- 748
- 749 43. Vats D, *et al.* Oxidative metabolism and PGC-1beta attenuate macrophage-mediated
750 inflammation. *Cell Metab* **4**, 13-24 (2006).
- 751
- 752 44. Kolliniati O, Ieronymaki E, Vergadi E, Tsatsanis C. Metabolic Regulation of Macrophage Activation.
753 *J Innate Immun*, 1-17 (2021).
- 754
- 755 45. El-Diwany R, *et al.* CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction
756 in humans. *Sci Adv* **4**, eaat0843 (2018).
- 757
- 758 46. Lai JH, *et al.* Mitochondrial CMPK2 mediates immunomodulatory and antiviral activities through
759 IFN-dependent and IFN-independent pathways. *iScience* **24**, 102498 (2021).
- 760
- 761 47. Liu W, *et al.* Identification of fish CMPK2 as an interferon stimulated gene against SVCV infection.
762 *Fish Shellfish Immunol* **92**, 125-132 (2019).

763

- 764 48. Lai JH, Hung LF, Huang CY, Wu DW, Wu CH, Ho LJ. Mitochondrial protein CMPK2 regulates IFN
765 alpha-enhanced foam cell formation, potentially contributing to premature atherosclerosis in SLE.
766 *Arthritis Res Ther* **23**, 120 (2021).
- 767
- 768 49. Huang X, Li Y, Fu M, Xin HB. Polarizing Macrophages In Vitro. *Methods Mol Biol* **1784**, 119-126
769 (2018).
- 770
- 771 50. Wang P, *et al.* Both decreased and increased SRPK1 levels promote cancer by interfering with
772 PHLPP-mediated dephosphorylation of Akt. *Mol Cell* **54**, 378-391 (2014).
- 773
- 774 51. Ó Maoldomhnaigh C, *et al.* Lactate Alters Metabolism in Human Macrophages and Improves Their
775 Ability to Kill Mycobacterium tuberculosis. *Frontiers in Immunology*, 4104 (2021).
- 776
- 777 52. Ravanelli S, den Brave F, Hoppe T. Mitochondrial Quality Control Governed by Ubiquitin. *Front*
778 *Cell Dev Biol* **8**, 270 (2020).
- 779
- 780 53. Wrobel L, *et al.* Mistargeted mitochondrial proteins activate a proteostatic response in the
781 cytosol. *Nature* **524**, 485-488 (2015).
- 782
- 783 54. Dobin A, *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15-21 (2013).
- 784
- 785 55. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput sequencing
786 data. *Bioinformatics* **31**, 166-169 (2015).
- 787
- 788 56. Subramanian A, *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting
789 genome-wide expression profiles. *Proc Natl Acad Sci U S A* **102**, 15545-15550 (2005).
- 790
- 791 57. Frezza C, Cipolat S, Scorrano L. Organelle isolation: functional mitochondria from mouse liver,
792 muscle and cultured fibroblasts. *Nat Protoc* **2**, 287-295 (2007).
- 793
- 794
- 795